RSV Treatment

Children's Healthcare of Atlanta is opening a 10-acre mental health center, thanks to donor funds - GPB News

Get link
Facebook
X
Pinterest
Email
Other Apps

November 28, 2022

Skip to main content

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

Local family warns parents about RSV, as number of infant cases increases - KLRT - FOX16.com

January 02, 2020

Local family warns parents about RSV, as number of infant cases increases KLRT - FOX16.com

Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial | Vaccines | News Channels - PipelineReview.com

March 21, 2019

Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial | Vaccines | News Channels PipelineReview.com Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial.

Oishei Children's Hospital Seeing Spike in RSV Cases - Spectrum News

December 30, 2019

Oishei Children's Hospital Seeing Spike in RSV Cases Spectrum News

Powered by Blogger

Theme images by Michael Elkan

Commentary: Part 3 - The Hospital/Doctor - Texas Scorecard

July 18, 2019

Commentary: Part 3 - The Hospital/Doctor Texas Scorecard This is the third of a four-part series on a case study of liberty loss through government overreach, particularly in the case of the Pardo family.

Gastrointestinal (GI) cancers: After Kate Middleton's diagnosis, here's what abdominal symptoms you should look out ...

May 10, 2024

rsv in older adults :: Article Creator RSV Vaccine Could Protect High-Risk Adults Under 60, Pfizer Says Topline A late-stage trial of Pfizer's RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to expand the vaccine's availability to more people who are at a higher risk to the potentially lethal infection. Pfizer said the shot—approved for adults age 60 and older—had similar effects in adults over age 18. ... [+] Getty Images Key Facts Pfizer's vaccine, marketed as Abrysvo, resulted in an immune response in adults aged 18 to 59 who are at a higher risk of RSV disease because of underlying medical conditions after a single dose, the company said. The immune response was not worse than the response observed in adults aged 60 and above, whom the Food and Drug Administration approved the vaccine for l...